This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): etaracizumab, MEDI522, MEDI-522, Vitaxin
Description: Vitaxin is an antibody that has the potential to inhibit the progression of a variety of diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, and certain forms of cancer and eye disease. Vitaxin appears to work by binding to a specific integrin (alpha-V-beta-3) expressed on a number of cells, such as newly forming blood vessels (angiogenesis), bone resorbing osteoclasts, and activated macrophages. Both angiogenesis and osteoclast-mediated osteolysis (bone destruction) are key elements involved in the development of rheumatoid arthritis.
Deal Structure: In February 1999, AMEV (now part of Eli Lilly) entered into a four-antibody corporate collaboration with MedImmune. The agreement covers the licensing of Vitaxin to MedImmune as well as the optimization of three additional antibodies, including Synagis and an antibody against IL-9. Licenses granted under this agreement are exclusive and worldwide covering the right to research, develop, sell and sublicense. The business terms of the agreement includes research and development support, potential milestone payments, royalties on the sales of products resulting from the collaboration and an equity investment. The duration of the research and development aspect of this agreement was extended through February 2004.
In June 2007, AstraZeneca closed its acquisition of MedImmune.
Partners: AstraZeneca PLC
Additional information available to subscribers only: